Nulong-Trio 10 Tablets

babies: not applicable. lactating mothers: it is not known whether it is safe, please consult your doctor. pregnancy: it is contraindicated in pregnancy.
limited studies have shown harmful effects on the developing baby. please consult your doctor. driving: chlorthalidone, clinidipine, olmesartan medoxmil tablet may cause excessive drowsiness.
do not drive if this symptoms occur. alcohol: chlorthalidone, clinidipine, olmesartan medoxmil tablet may decrease alertness, affects vision and may cause dizzy and sleep.
do not drive if this symptoms occur. kidney: chlorthalidone, clinidipine, olmesartan medoxmil tablet should be used with caution in patients with kidney disease.
dosage adjustment may be needed. please consult your doctor. liver: chlorthalidone, clinidipine, olmesartan medoxmil tablet should be used with caution in patients with liver disease.
dosage adjustment may be needed. please consult your doctor..

Ankle swelling Headache Dizziness Tiredness Palpitations Sleepiness Increased blood uric acid Glucose intolerance Stomach upset Flushing.

NULONG TRIO tablet is an anti – hypertensive, it works by relaxing blood vessels thereby reducing the blood pressure.

If you miss a dose of NULONG TRIO, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• NULONG TRIO tablet is an anti – hypertensive and used to treat hypertension • it helps to lower high blood pressure thus reduce the chances of future heart attack and stroke • the tablet may decrease alertness, affects vision and may cause dizziness and sleep. do not drive if these symptoms occur • the tablet may cause dehydration.
drink plenty of fluids and inform your doctor, if you develop extreme thirst, muscle weakness or dry mouth • you need to inform your doctor if you are pregnant or intend to become pregnant.

• clinidipine + adenosine: concurrent use leads to increase the arrhythmogenic activities of cilnidipine • clinidipine + acetyl salicylic acid: concurrent use leads to increase the risk or severity of hyperkalemia • olmesarton medoxmil + almotriptan: concurrent use leads to decrease the antihypertensive activities of olmesartan • olmesarton medoxmil +alfuzosin: concurrent use leads to increase the hypotensive activities of olmesartan serious • chlorothalidone + aminoglutithiamide: concurrent use leads to increased toxicity by pharmacodynamic synergism • chlorothalidone + squill: concurrent use leads to increases in the toxicity of squill.